LOCATIONS: NEW YORK CITY | LONG ISLAND
BOOK YOUR CONSULTATION NOW: 917-261-7370
For adults living with treatment-resistant depression, SPRAVATO® (esketamine) is an FDA-approved nasal spray option. At our Melville office, New York Ketamine Infusions provides supervised SPRAVATO® care for eligible patients from communities across Long Island.
When previous antidepressant treatment has not brought sufficient improvement, our clinical team can evaluate whether SPRAVATO® is an appropriate option and assist with reviewing potential insurance benefits.
SPRAVATO® is a prescription form of esketamine delivered as a nasal spray and FDA-approved for certain adults with treatment-resistant depression. It is given only in a certified medical setting. Patients administer the nasal spray themselves under supervision and remain at the clinic for monitoring for at least two hours afterward.
150 Broadhollow Rd, Suite 103
Melville, NY 11747
SPRAVATO® is FDA-approved for adults with treatment-resistant depression.
Many commercial, Medicare and Medicaid plans may provide coverage for eligible patients.
Treatment is administered in-office with required medical observation afterward.
Treatment-resistant depression refers to depression that continues despite adequate trials of antidepressant therapy. Some patients still experience significant symptoms after trying multiple medications.
SPRAVATO® takes a different pharmacologic approach from many conventional antidepressants. Esketamine primarily affects NMDA receptors and glutamate signaling rather than focusing mainly on serotonin or norepinephrine pathways.
New York Ketamine Infusions provides medically supervised SPRAVATO® treatment for eligible adults with treatment-resistant depression.
Unlike many traditional antidepressants, esketamine acts as an NMDA receptor antagonist and influences glutamate signaling, one of the brain’s major communication systems.
Esketamine acts primarily through NMDA and glutamate pathways rather than relying solely on the neurotransmitter systems targeted by many traditional antidepressants.
SPRAVATO® has been specifically studied in adults whose depression has not responded adequately to previous antidepressant treatment.
Treatment response varies. Your clinical team monitors symptoms, tolerability and progress to determine whether continued treatment is appropriate.
Before dosing, the clinical team reviews pertinent health information and measures your blood pressure.
SPRAVATO® is self-administered as a nasal spray while a healthcare professional directly observes the treatment.
After administration, you stay in the healthcare setting for at least two hours so the clinical team can observe your response.
You will need transportation home after your appointment and should avoid driving until the next day following a restful night of sleep.
SPRAVATO® is usually scheduled more often at the beginning of treatment, with visits becoming less frequent over time when clinically appropriate. Your provider adjusts the schedule according to your response and individual needs.
Typically twice weekly
Typically once weekly
Weekly or every 2 weeks based on clinical need
Treatment schedules are individualized. Your provider determines dosing frequency and whether continued treatment is appropriate.
Although SPRAVATO® and IV ketamine are related, they are distinct treatments with different formulations and methods of administration.
SPRAVATO® uses esketamine in a nasal spray, whereas IV ketamine uses racemic ketamine delivered through an intravenous infusion.
Coverage considerations may differ as well. Because SPRAVATO® has FDA approval for specific depression indications, qualifying patients may have insurance benefits for treatment. IV ketamine for depression is used off-label and is commonly self-pay.
Compare Ketamine vs. SPRAVATO® in MelvilleEsketamine nasal spray • FDA-approved for specific depression indications • In-office administration • Insurance coverage may be available.
Racemic ketamine • Intravenous administration • Used off-label for depression • Often self-pay for psychiatric treatment.
Eligible patients with treatment-resistant depression may have SPRAVATO® benefits through many health plans. Actual coverage is determined by the individual policy, diagnosis, prior treatment history, medical-necessity criteria and any authorization requirements.
The New York Ketamine Infusions team can help clarify SPRAVATO® insurance coverage in New York, verify benefits and explain the authorization process before treatment.
For eligible SPRAVATO® patients, New York Ketamine Infusions works with many commercial, Medicare, Medicaid, military, employer-sponsored and behavioral-health insurance plans.
Insurance participation and coverage vary by individual plan, medical necessity, prior authorization requirements, and eligibility. If you don't see your insurance listed, contact our team—we're happy to verify your benefits and determine whether SPRAVATO® treatment may be covered.
Our Long Island SPRAVATO® office is located at 150 Broadhollow Rd, Suite 103, Melville, NY 11747, where New York Ketamine Infusions provides medically supervised treatment for eligible patients.
Our Melville location serves patients throughout Long Island, including Melville, Huntington, Dix Hills, Farmingdale, Plainview, Bethpage, Commack, Deer Park, and surrounding Nassau and Suffolk County communities.
Since SPRAVATO® requires an observation period after dosing and patients may not drive themselves home, proximity to the clinic and transportation arrangements are important practical considerations.
Learn more about SPRAVATO® treatment at New York Ketamine Infusions →
150 Broadhollow Rd, Suite 103
Melville, NY 11747
Phone: 631-629-4626
Treatment Hours:
Monday, Wednesday & Friday: 9 AM–5 PM
Explore your next step with New York Ketamine Infusions. Contact our team to discuss an appointment and learn about potential insurance coverage for SPRAVATO® treatment at our Melville, Long Island office.
Certain adults with treatment-resistant depression may be candidates for SPRAVATO®. Eligibility requires a clinical evaluation of your diagnosis, previous antidepressant trials, current medications, medical history and possible contraindications.
Coverage may be available through many commercial insurance, Medicare and Medicaid plans for eligible patients. Benefits vary according to the plan, medical-necessity criteria, treatment history and authorization rules. Learn more about SPRAVATO® insurance coverage.
Eligible patients may receive New York Medicaid coverage for SPRAVATO® depending on their plan, clinical requirements and authorization criteria. See our guide to Medicaid coverage for SPRAVATO® in New York.
No. SPRAVATO® is administered only in a certified healthcare setting, where the patient self-administers the nasal spray under direct observation. Monitoring continues for at least two hours after dosing.
Patients must arrange a ride after treatment. Driving and other activities requiring complete alertness should wait until the next day after a restful night of sleep.
No. SPRAVATO® contains esketamine delivered by nasal spray, while IV ketamine is racemic ketamine delivered intravenously. Review our detailed ketamine vs. SPRAVATO® comparison for New York.
Plan for at least two hours of post-dose monitoring, plus additional time for preparation, administration and the clinical assessment surrounding treatment.
The first step is a clinical consultation. Our team can review your treatment history, assess whether SPRAVATO® may be appropriate for you and help check applicable insurance benefits.
During a consultation, the clinical team can assess whether SPRAVATO® fits your treatment history and help determine whether your health plan may offer coverage.
Request Your Consultation